A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
non–small-cell non–small-cell lung cancer,uncommon egfr mutations,lung cancer,sutetinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要